Results for "Biotech developer"

Several publicly traded firms, including biotech developer Immatics, are experiencing heightened engagement from activist shareholders pushing for strategic or operational changes.

A diverse group of publicly traded firms, including retailers, biotech developers, and technology providers, have announced their participation in forthcoming investor conferences. These events will allow management teams to update shareholders on strategic initiatives and financial performance.